Patents by Inventor Paul L. Skatrud

Paul L. Skatrud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6322998
    Abstract: The present invention provides DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Cephalosporium, and Aspergillus.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Cathleen A. Cantwell, Roland L. Hodges, JoAnn Hoskins, Stephen W. Queener, Paul L. Skatrud
  • Patent number: 6180361
    Abstract: The present invention provides DNA compounds that encode the expandase/hydroxylase enzyme of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a variety of host cells, including E. coli, Penicillium, and Cephalosporium.
    Type: Grant
    Filed: December 12, 1988
    Date of Patent: January 30, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud
  • Patent number: 6143868
    Abstract: The invention provides isolated nucleic acid compounds encoding a novel MTG of Staphylococcus aureus. Also provided are vectors and transformed heterologous host cells for expressing the MTG and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the MTG.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: November 7, 2000
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Stanley R. Jaskunas, Jr., Robert B. Peery, Paul L. Skatrud
  • Patent number: 5922540
    Abstract: The invention provides isolated nucleic acid compounds encoding a novel MTG of Staphylococcus aureus. Also provided are vectors and transformed heterologous host cells for expressing the MTG and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the MTG.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: July 13, 1999
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Stanley R. Jaskunas, Jr., Robert B. Peery, Paul L. Skatrud
  • Patent number: 5919617
    Abstract: The present invention provides novel methods and materials for detecting the presence of a fungus in a biological sample. The inventive methods and materials exploit the fact that the amino acid sequence of the saccharopine dehydrogenase molecule is highly conserved in fungi. Inventive hybridization probes, nucleic acids, PCR primers, antibodies, epitopes, reagents and methods are provided.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: July 6, 1999
    Assignee: Miami University
    Inventors: Jnanendra K. Bhattacharjee, Richard C. Garrad, Paul L. Skatrud, Robert B. Peery
  • Patent number: 5776695
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene ddl of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the DDL enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: July 7, 1998
    Assignee: Eli Lilly and Company
    Inventors: Paul L. Skatrud, Robert B. Peery
  • Patent number: 5776733
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene ddl of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the DDL enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: July 7, 1998
    Assignee: Eli Lilly and Company
    Inventors: Paul L. Skatrud, Robert B. Peery
  • Patent number: 5773214
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus flavus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus flavus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: June 30, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert B. Peery, Paul L. Skatrud
  • Patent number: 5770415
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: June 23, 1998
    Assignee: Eli Lilly and Company
    Inventors: Paul L. Skatrud, Robert B. Peery
  • Patent number: 5710018
    Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 20, 1998
    Assignee: Eli Lilly and Company
    Inventors: Anne H. Dantzig, Jo Ann Hoskins, Paul L. Skatrud
  • Patent number: 5705352
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus fumigatus. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus fumigatus MDR-1 are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: January 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert B. Peery, Paul L. Skatrud
  • Patent number: 5691161
    Abstract: The invention provides isolated nucleic acid compounds encoding the stem peptide biosynthetic gene murA of Streptococcus pneumoniae. Also provided are vectors and transformed heterologous host cells for expressing the MurA enzyme product and a method for identifying compounds that inhibit stem peptide biosynthesis.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: November 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: Paul L. Skatrud, Robert B. Peery
  • Patent number: 5620855
    Abstract: The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: April 15, 1997
    Assignee: Eli Lilly and Company
    Inventors: Anne H. Dantzig, Jo A. Hoskins, Paul L. Skatrud
  • Patent number: 5587307
    Abstract: The instant invention provides the femA gene of Staphylococcus epidermidis and all degenerate sequences thereof, the protein encoded by the femA gene (FemA), and vectors and microorganisms comprising genes encoding the FemA protein.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: December 24, 1996
    Assignee: Eli Lilly and Company
    Inventors: William E. Alborn, Jr., JoAnn Hoskins, Paul L. Skatrud, Serhat Unal
  • Patent number: 5516655
    Abstract: The invention provides isolated nucleic acid compounds encoding the multiple drug resistance protein of Aureobasidium pullulans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aureobasidium pullulans are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: April 20, 1994
    Date of Patent: May 14, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert B. Peery, Paul L. Skatrud
  • Patent number: 5070020
    Abstract: The present invention provides DNA compounds that encode deacetoxycephalosporin C synthetase (DAOCS) activity. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Streptomyces, Aspergillus, and Cephalosporium.
    Type: Grant
    Filed: May 9, 1988
    Date of Patent: December 3, 1991
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Steven Kovacevic, James R. Miller, Paul L. Skatrud
  • Patent number: 4892819
    Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase. The invention also comprises methods, transformants, and polypeptides related to the novel DNA compounds. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcription and translation activating sequence, was isolated from Penicillium chrysogenum. The isopenicillin N synthetase-encoding DNA can be used to construct novel E. coli expression vectors that drive expression of isopenicillin N synthetase in E. coli. The intact P. chrysogenum isopenicillin N synthetase-encoding DNA and associated transcription and translation activating sequence can also be used to construct expression vectors that drive expression of the isopenicillin N synthetase in P. chrysogenum and Cephalosporium acremonium. The transcription and translation activating sequence can be fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto expression vectors that function in P. chrysogenum and C.
    Type: Grant
    Filed: November 25, 1985
    Date of Patent: January 9, 1990
    Assignee: Eli Lilly and Company
    Inventors: Lucinda G. Carr, Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud
  • Patent number: 4885251
    Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase and also comprises related methods, transformants, and polypeptides. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcriptional and translational activating sequence, was isolated from Cephalosporium acremonium and cloned into an E. coli cloning vector. The isopenicillin N synthetase-encoding DNA has been used to construct novel E. coli expression vectors that drive expression of a stable, active, and novel isopenicillin N synthetase in E. coli. The intact C. acremonium isopenicillin N synthetase-encoding DNA and associated transcriptional and translational activating sequence have also been used to construct C. acremonium expression vectors that drive expression of the isopenicillin N synthetase in C. acremonium. The C. acremonium transcriptional and translational activating sequence has further been fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto C.
    Type: Grant
    Filed: August 8, 1986
    Date of Patent: December 5, 1989
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud, Otis W. Godfrey
  • Patent number: 4885252
    Abstract: DNA compounds and recombinant DNA expression vectors that encode and drive expression in recombinant host cells of the isopenicillin N synthetase activity of Aspergillus nidulans are useful to produce isopenicillin N synthetase and to improve the yield of .beta.-lactam-containing antibiotics from antibiotic-producing organisms. The isopenicillin N synthetase gene of A. nidulans can be isolated from plasmid pOGOO4, available from the Northern Regional Research Center under the accession number NRRL B-18171.
    Type: Grant
    Filed: December 14, 1987
    Date of Patent: December 5, 1989
    Assignee: Eli Lilly and Company
    Inventors: Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud, Barbara J. Wiegel
  • Patent number: 4762786
    Abstract: A method for transforming Cephalosporium and other lower eukaryotes is disclosed. The method involves inserting a recombinant DNA cloning vector comprising a Saccharomyces cerevisiae transcriptional and translational activating sequence positioned for expression of hygromycin phosphotransferase into a host cell and then growing the host cell under selective conditions. The vectors optionally further comprise Cephalosporium ribosomal DNA and also sequences that allow for replication and selection in E. coli and Streptomyces.
    Type: Grant
    Filed: September 27, 1984
    Date of Patent: August 9, 1988
    Assignee: Eli Lilly and Company
    Inventors: Jerry L. Chapman, Jr., Thomas D. Ingolia, Kevin R. Kaster, Stephen W. Queener, Paul L. Skatrud